Skip to content

Evaluation of the use of ketamine medication in the treatment of depressed or bipolar persons

Sublingual Ketamine in treatment of Mood Disorders

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-472gf3
Enrollment
Unknown
Registered
2016-07-11
Start date
2016-07-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder, bipolar disorder, suicide risk

Interventions

Our strategy will be to start with a very low dose (0.3 ml) of racemic ketamine 50 mg/ml (i.e. 15 mg) administered sublingually, allowed to absorb for 5 min and swallowed. Then we considered the inter
Drug

Sponsors

Hospital São José
Lead Sponsor
Hospital São José
Collaborator

Eligibility

Age
16 Months to 59 Years

Inclusion criteria

Inclusion criteria: Volunteers who have any mood disorders and high risk of suicide; 16-59 years old.

Exclusion criteria

Exclusion criteria: Volunteers manifesting delusions or maniac symptoms to mental status examination or BPRS; an actual history of alcohol or substance dependence with recent use in the last 7 days except nicotine and benzodiazepines; an unstable or untreated medical disorder; severe exogenous intoxication; being pregnant.

Design outcomes

Primary

MeasureTime frame
Reduction of the depressive symptoms during the intervention period (maximum 14 days) assessed by the instrument Montgomery Asberg Depression Rating Scale (MADRS) from the reduction of at least 50% in pre and post-intervention measurements.

Secondary

MeasureTime frame
Reduction of suicidal ideation during the intervention period (maximum 14 days) assessed by the instrument Beck Scale for Suicide Ideation (BSI) from the reduction of at least 50% in pre and post-intervention measurements.

Countries

Brazil

Contacts

Public ContactRafael;Rafael Araújo;de Araújo

Hospital São José;Hospital São José

rmpsiquiatria@gmail.com;rmpsiquiatria@gmail.com51 37161219;+55 (51) 3716 1219

Outcome results

None listed

Source: REBEC (via WHO ICTRP)